Antiinfectives Update: Focus on Treatment and Prevention of Viral and Associated Infections

Abstract

Spanish

French

OBJECTIVE:

To review the clinically significant antiinfectives approved by the Food and Drug Administration (FDA) since 1996, with an emphasis on agents used for treatment, prevention, or suppression of infection in immunocompromised individuals.

DATA SOURCES:

A MEDLINE search covering November 1994 to March 1998 was conducted to identify all antiinfectives (new medications and old medications with new indications) and the pertinent literature for review. The search was updated in August 1998 and supplemented with an FDA listing of approved drugs to enhance completeness.

STUDY SELECTION:

Clinically relevant studies were selected to highlight specific points about each medication. Preclinical publications were used when sufficient information was not available from clinical trials and this information was needed for clinical practice.

CONCLUSIONS:

Several new and promising antiretroviral agents (stavudine, lamivudine, saquinavir soft-gel capsules, nelfinavir, efavirenz) have been approved, which may allow more options to control HIV viremia. New options for treatment, prevention, and suppression of infections in immunocompromised individuals include azithromycin, cidofovir, famciclovir, valacyclovir, and itraconazole suspension. Liposomal-based amphotericin products may be associated with less toxicity than conventional amphotericin B; however, superior efficacy has not been proven.

Keywords

antiinfectives stavudine lamivudine saquinavir nelfinavir efavirenz azithromycin cidofovir famciclovir valacyclovir itraconazole liposomal amphotericin B

Get full access to this article

View all access options for this article.

References

Briceland

Cleary

Fletcher

Healy

Peloquin

. Recent advances: Antiinfectives. Ann Pharmacother 1995;29: 1035–40.

World AIDS Day — December 1, 1996. MMWR Morb Mortal Wkly Rep 1996;45:1.

World Health Organization. HIV/AIDS: The global epidemic. Wkly Epidemiol Rec 1997;72:1–5.

Mellors

Kingsley

Rinaldo

Jr Todd

Hoo

Kokka

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573–9.

Havlir

Richman

. Viral dynamics of HIV: Implications for drug development and therapeutic strategies. Ann Intern Med 1996;124: 984–94.

Carpenter

CCJ

Fischl

Hammer

Hirsch

Jacobsen

Katzenstein

Antiretroviral therapy for HIV infection in 1998, updated recommendations of the International AIDS Society-USA panel. JAMA 1998;280:78–86.

Package insert. Fortovase (saquinavir) soft gelatin capsules. Nutley, NJ: Roche Pharmaceuticals, 1997.

D'Aquila

Hughes

Johnson

Fischl

Sommadossi

Liou

Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996;124:1019–30.

Package insert. Viramune (nevirapine). Columbus, OH: Roxane Laboratories, June 1996.

10.

Package insert. Rescriptor (delavirdine). Kalamazoo, MI: Pharmacia & Upjohn, 1997.

11.

Kew

Salomon

Olsen

Wainberg

Prasad

. The nucleoside analog-resistant e89g mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors. Antimicrob Agents Chemother 1996;40: 1711–4.

12.

Richman

Havlir

Corbeil

. Nevirapine resistance mutations of human immunodeficiency virus type-1 selected during therapy. J Virol 1994;63: 1660–8.

13.

Hughes

Johnson

Hirsch

Bremer

Elbeik

Erice

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929–38.

14.

O'Brien

Hartigan

Daar

Simberkoff

Hamilton

. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997;126: 939–45.

15.

Powderly

Landay

Lederman

. Recovery of the immune system with antiretroviral therapy, the end of opportunism? JAMA 1998;280: 72–7.

16.

Saag

Holodniy

Kuritzkes

O'Brien

Coombs

Poscher

HIV viral load markers in clinical practice. Natl Med 1996;2:625–9.

17.

Mansky

Temin

. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995;69: 5087–94.

18.

Hertogs

Mellors

Schel

Van Cauwenberghe

Larder

Kemp

Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates (abstract). Published proceedings of the 5th Conference on Retrovirus and Opportunistic Infections. Chicago, IL, February 1–5, 1998:395.

19.

Lawrence

Schapiro

Winters

Montoya

Zolopa

Pesano

Salvage therapy with indinavir plus nevirapine in patients previously treated with two other protease inhibitors and multiple reverse transcriptase inhibitors (abstract). Published proceedings of the 5th Conference on Retrovirus and Opportunistic Infections. Chicago, IL, February 1–5, 1998:422.

20.

1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997;46(RR-12).

21.

Tseng

Foisy

. Mangement of drug interactions in patients with HIV. Ann Pharmacother 1997;31: 1040–58.

22.

Dickover

Garratty

Herman

Sim

Plaeger

Boyer

Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: Effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599–605.

23.

Public Health Service task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998;47(RR-2).

24.

Conner

Sperling

Gelber

Kiseler

Scott

O'Sullivan

Reduction of maternal—infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173–80.

25.

Spector

McKinley

Lalezari

Samo

Andruczk

Follansbee

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996;334:1491–7.

26.

Nicklin

. Oral ganciclovir as prophylaxis against cytomegalovirus (letter). N Engl J Med 1996;335:1395.

27.

Drew

Ives

Lalezari

Crumpacker

Follansbee

Spector

Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615–20.

28.

The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995;9: 471–7.

29.

Brown

Arum

Francis

Patel

Malcolm

. Ganciclovir prodrug (RS-79070)–multiple dose, dose-ranging study with effect of food (abstract). Published proceedings of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22–26, 1997:LB19.

30.

Martin

Parks

Mellow

Ferris

Walton

Remaley

Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch Ophthalmol 1994;112:1531–9.

31.

Package insert. Vitrasert (ganciclovir). La Jolla, CA: Agouron Pharmaceuticals, 1997.

32.

Lalezari

Stagg

Kuppermann

Holland

Kramer

Ives

Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1997;126:257–63.

33.

Package insert. Vistide (cidofovir). Foster City, CA: Gilead Sciences, Inc., 1996.

34.

Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC Peripheral Cytomegalovirus Retinitis Trial. Ann Intern Med 1997;126: 264–74.

35.

Horsburgh

Havlik

Ellis

Kennedy

Fann

Bubois

Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991;144:557–9.

36.

Nightingale

Cameron

Gordin

Sullam

Cohn

Chaisson

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828–33.

37.

Pierce

Crampton

Henry

Heifets

LaMarca

Monteclavo

. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335: 384–91.

38.

Havlir

Dube

Sattler

Forthal

Kemper

Dunne

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392–8.

39.

Acosta

Fletcher

. Valacyclovir. Ann Pharmacother 1997;31: 185–91.

40.

Perry

Faulds

. Valacyclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996;52: 754–72.

41.

Perry

Wagstaff

. Famciclovir: A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995;40: 396–415.

42.

Jackson

Gibbons

Meyer

Inouye

. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997;157: 909–12.

43.

Wood

Dworkin

Soong

Whitley

. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials. Clin Infect Dis 1996;22: 341–7.

44.

Whitley

Weiss

Gnann

Jr Tyring

Mertz

Pappas

Acyclovir with and without prednisone for the treatment of herpes zoster. Ann Intern Med 1996;125:376–83.

45.

Beutner

Friedman

Forszpaniak

Anderson

Wood

. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39: 1546–53.

46.

Degreef

. the Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994;4: 241–6.

47.

Candaele

. Famciclovir: Confirmed efficacy of 250 mg t.i.d. for the treatment of herpes zoster infection (abstract). Antiviral Res 1994;23 (suppl 1):98.

48.

Zingman

Azckin

Wheat

Rajicic

Schneider

Mahon

Amphotericin B oral suspension for fluconazole-resistant oral candidiasis in HIV-infected patients (abstract). Published proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, September 28-October 1, 1997:K15.

49.

Cleary

. Amphotericin B formulated in a lipid emulsion. Ann Pharmacother 1996;30: 409–12.

50.

Anaissie

White

Uzun

Singer

Bodey

Matzke

Amphotericin B lipid complex versus amphotericin B for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial (abstract). Published proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 18, 1997:LM21.

51.

Walsh

Finberg

Arndt

Hiemenz

Schwartz

Bodensteiner

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study group. N Engl J Med 1999;340: 764–71.

52.

Trépanier

Amsden

. Current issues in onychomycosis. Ann Pharmacother 1998;32: 204–14.

53.

Watson

Goodnow

Levenson

Todd

Nelson

Banghart

. Varicella-related deaths among adults — United States. MMWR Morb Mortal Wkly Rep 1997;46: 409–12.

54.

Gilden

Mahalingam

Dueland

Cohrs

. Herpes zoster: Pathogenesis and latency. Prog Med Virol 1992;39: 19–75.

55.

Holmes

Reef

Hadler

Williams

Warton

. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;45 (RR-11).

56.

Oxman

. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995;45 (12 suppl 8):S41–6.

57.

Huse

Meissner

Lacy

Oster

. Childhood vaccination against chickenpox: An analysis of benefit and costs. J Pediatr 1994;124: 869–74.

58.

Lieu

Black

Rieser

Ray

Lewis

Shinefield

. The cost of childhood chickenpox: Parent's perspective. Pediatr Infect Dis J 1994;13: 173–7.

59.

Package insert. Varivax (varicella virus vaccine live). West Point, PA: Merck & Co., 1995.

60.

Recommendations of the Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization. MMWR Morb Mortal Wkly Rep 1996;45(RR-15).

61.

Centers for Disease Control and Prevention. Hepatitis surveillance report no. 56. April 1996.

62.

Glickson

Galun

Oren

Tur-Kaspa

Shouval

. Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine 1992;71: 14–23.

63.

Lemon

Shapiro

. The value of immunization against hepatitis A. Infect Agents Dis 1994;1: 38–49.

64.

Werzberger

Mensch

Kuter

Brown

Lewis

Sitrin

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453–7.

65.

Innis

Snitbhan

Kunasol

Laorakpongse

Poopatanakool

Kozik

Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:28–34.

66.

McMahon

Beller

Williams

Schloss

Tanttila

Bulkow

. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 1996;15: 733–9.

67.

Prevention of hepatitis A through active or passive immunization. MMWR Morb Mortal Wkly Rep 1996;45(RR-15).